FILE PHOTO: A logo of Sanofi is seen at the Sanofi’s Doliprane production site in Compiegne, France, October 17, 2024. REUTERS/Sarah Meyssonnier/File Photo
FILE PHOTO: A logo of Sanofi is seen at the Sanofi’s Doliprane production site in Compiegne, France, October 17, 2024. REUTERS/Sarah Meyssonnier/File Photo